The Rescue Use of A Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab; Reo-Pro ) in High-Risk Patients with Acute Myocardial Infarction Underwent Percutaneous Coronary Intervention.
10.4070/kcj.2001.31.5.492
- Author:
Weon KIM
;
Myung Ho JEONG
;
Kye Hun KIM
;
Jong Cheol PARK
;
Sang Hyun LEE
;
Jae Young RHEW
;
Kyung Tae KANG
;
Nam Ho KIM
;
Kun Hyung KIM
;
Young Keun AHN
;
Jeong Gwan CHO
;
Jong Chun PARK
- Publication Type:Original Article
- MeSH:
Blood Platelets*;
Death;
Glycoproteins*;
Hemorrhage;
Humans;
Jeollanam-do;
Male;
Myocardial Infarction*;
Percutaneous Coronary Intervention*
- From:Korean Circulation Journal
2001;31(5):492-499
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGRUOND: Platelets are known to play a major role in the ischemic complications of percutaneous coronary intervention (PCI). Accordingly, we evaluated the effect of rescue use of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab; Reo-Pro ) in Korean patients with acute myocardial infarction (AMI) at high risk for the ischemic complications who underwent PCI. METHOD: Sixty eight patients (54 male, 59.1+/-9.96 years) treated by the rescue use of Reo-Pro out of 1,117 patients underwent PCI at Chonnam National University Hospital from Mar 1999 to Feb 2000. All of target lesions were thrombus-containing lesions in patients with AMI. The primary end points consisted of any of the followings : cardiac death, nonfatal MI, repeated revascularization. The number of end-point events were tabulated at 6 months after PCI. RESULTS: The primary success rate was 92.6% (63/68). At primary end points, there were 5 cases (7.3%), composed of 2 deaths (2.9%), 1 MI, 2 repeated revascularization (2.9%). There was no major bleeding complication after PCI. At secondary end point, there were 23 cases (34.9%) including primary end point, composed of 3 deaths (4.4%), 1 MI and 19 revascularization (28.0%). CONCLUSION: The rescue Reo-Pro can be used safely and effectively in high-risk Korean patients with AMI.
